ReviewCurrent oncology (Toronto, Ont.)2026

First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma.

Robert Puckrin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.